OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
Ariadna Bartoló‐Ibars, Mireia Uribe‐Herranz, Guillermo Muñoz‐Sánchez, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4664-4664
Open Access | Times Cited: 16

Showing 16 citing articles:

CAR-T cell combination therapy: the next revolution in cancer treatment
Maysoon Al‐Haideri, Santalia Banne Tondok, Salar Hozhabri Safa, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 88

Strategies to enhance CAR-T persistence
Yue Liu, Lingna An, Ruihao Huang, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 53

Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing
Muna Qayed, Joseph P. McGuirk, Gary D. Myers, et al.
Cytotherapy (2022) Vol. 24, Iss. 9, pp. 869-878
Open Access | Times Cited: 42

Recent updates on allogeneic CAR-T cells in hematological malignancies
Shafieeh Mansoori, Ahmad Noei, Amirhosein Maali, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 7

CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option
Györgyi Műzes, Ferenc Sípos
Cells (2023) Vol. 12, Iss. 11, pp. 1534-1534
Open Access | Times Cited: 10

Leukapheresis for CAR-T cell production and therapy
Ilias Pessach, Arnon Nagler
Transfusion and Apheresis Science (2023) Vol. 62, Iss. 6, pp. 103828-103828
Closed Access | Times Cited: 9

Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development
Lorena Pérez-Amill, Álex Bataller, Julio Delgado, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8

Precision Targeting and Genetically Modified T Cells for Targeting Cancer Cells
Dr Ammar A. Razzak Mahmood, Sudhakar Srinivasan, Challaraj Emmanuel E. S
International Journal of Trends in OncoScience (2024), pp. 1-9
Open Access | Times Cited: 2

An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile
Xiaolong Wu, Ingo G.H. Schmidt‐Wolf
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8

The potential role of short chain fatty acids improving ex vivo T and CAR-T cell fitness and expansion for cancer immunotherapies
Adrián González-Brito, Mireia Uribe‐Herranz
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3

CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation
Isabel Martínez-Romera, Víctor Galán‐Gómez, Berta González‐Martínez, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 4

Stem cell therapies for combating emerging and reemerging viral infections
Popat Mohite, Abhijeet Puri, Jineetkumar Gawad
Elsevier eBooks (2024), pp. 157-176
Closed Access

Optimizing CAR-T Treatment: A T2EVOLVE Guide to Raw and Starting Material Selection
Sergio Navarro-Velázquez, Carole Moukheiber, Susana Inogés Sancho, et al.
Molecular Therapy (2024) Vol. 33, Iss. 3, pp. 847-865
Open Access

Page 1

Scroll to top